Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Conformationally Tuned Cyclic RGD Peptides for Integrin-Subtype-Selective PET/CT Imaging.

Journal of medicinal chemistry·2026
Same author

Development and Advantages of <i>O</i>-(Carboxymethyl)-<i>L</i>-tyrosine-Based PSMA-Targeting Theranostics for Prostate Cancer.

Journal of medicinal chemistry·2026
Same author

Efficacy of combined nutrition and exercise interventions on muscle health and performance in patients after a stroke: protocol for a systematic review and meta-analysis.

BMJ open·2026
Same author

Cross-Subject Event-Related Potential Classification via Multi-View Based Contrastive Learning.

Brain connectivity·2026
Same author

Associations between parental role modeling of physical activity and overweight and obesity in children and adolescents: words, actions, or both? A cross-sectional study of young children's population in Shanghai.

BMC public health·2026
Same author

Impact of a school based flag football intervention on fitness outcomes in Chinese children aged 9 to 11 years: a randomized controlled trial.

BMC public health·2026

Related Experiment Video

Updated: Jan 17, 2026

Development of a 68Gallium-Labeled D-Peptide PET Tracer for Imaging Programmed Death-Ligand 1 Expression
09:06

Development of a 68Gallium-Labeled D-Peptide PET Tracer for Imaging Programmed Death-Ligand 1 Expression

Published on: February 3, 2023

1.9K

Multicyclic Peptides Targeting PD-L1 for Radiotheranostics: From Discovery to Clinical Proof-of-Concept.

Xueting Cheng1, Shuo Jiang2, Xingtong Peng3

  • 1Department of Chemistry, College of Chemistry and Chemical Engineering, The MOE Key Laboratory of Spectrochemical Analysis and Instrumentation, State Key Laboratory of Physical Chemistry of Solid Surfaces, Xiamen University, Xiamen 361005, P.R. China.

Journal of the American Chemical Society
|September 20, 2025
PubMed
Summary
This summary is machine-generated.

Researchers developed a novel peptide, dmp10, for precision cancer therapy. This peptide targets programmed death-ligand 1 (PD-L1) and shows promise in both imaging and treating tumors, advancing radiotheranostics for PD-L1-driven cancers.

More Related Videos

Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction
10:18

Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction

Published on: July 7, 2023

1.7K
Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

1.1K

Related Experiment Videos

Last Updated: Jan 17, 2026

Development of a 68Gallium-Labeled D-Peptide PET Tracer for Imaging Programmed Death-Ligand 1 Expression
09:06

Development of a 68Gallium-Labeled D-Peptide PET Tracer for Imaging Programmed Death-Ligand 1 Expression

Published on: February 3, 2023

1.9K
Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction
10:18

Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction

Published on: July 7, 2023

1.7K
Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

1.1K

Area of Science:

  • Oncology
  • Molecular Imaging
  • Radiochemistry

Background:

  • Radiotheranostics offers personalized cancer treatment by combining diagnostics and therapy.
  • Targeting cell-surface antigens like programmed death-ligand 1 (PD-L1) is crucial but challenging due to antigen structure.
  • Existing ligands often lack the high affinity needed for flat, low-druggability targets such as PD-L1.

Purpose of the Study:

  • To develop a high-affinity ligand for PD-L1 to overcome limitations in radiotheranostics.
  • To engineer a novel disulfide-directed multicyclic peptide (DDMP) platform for targeting complex antigens.
  • To evaluate the diagnostic and therapeutic potential of the engineered peptide, dmp10, in preclinical and clinical settings.

Main Methods:

  • De novo discovery and rational engineering of disulfide-directed multicyclic peptides (DDMPs).
  • Iterative directed evolution combined with disulfide-directed library design to generate dmp10.
  • Preclinical evaluation using 68Ga-labeled dmp10 for PET imaging and 177Lu-labeled dmp10 for radionuclide therapy in murine models.
  • First-in-human pilot study to assess safety and efficacy in patients with solid tumors.

Main Results:

  • Generated dmp10, a ∼3 kDa peptide with picomolar affinity for PD-L1, exhibiting high shape complementarity.
  • 68Ga-dmp10 enabled high-contrast PET imaging of PD-L1+ tumors in mice (13.27 %ID/g uptake at 4h).
  • 177Lu-dmp10 eradicated 92.47% of established tumors in models with minimal off-target toxicity.
  • First-in-human study confirmed 68Ga-dmp10 tolerability and visualization of PD-L1+ lesions.

Conclusions:

  • Disulfide-directed multicyclic peptides (DDMPs) are a versatile platform for targeting geometrically complex antigens like PD-L1.
  • 68Ga/177Lu-labeled dmp10 demonstrates dual radiotheranostic utility for PD-L1-driven malignancies.
  • This work advances peptide design for ultrahigh-affinity binders and offers a promising agent for precision oncology.